Last update 07 Mar 2026

Del-1 gene therapy(Valentis, Inc.)

Overview

Basic Info

Drug Type
Gene therapy
Synonyms
Del-1 gene therapy, DELTAVASC, VLTS 589
Target
αvβ3
Action
modulators, inducers
Mechanism
αvβ3 modulators(Integrin alpha-V/beta-3 modulators), Angiogenesis inducers
Therapeutic Areas
Cardiovascular Diseases
Active Indication-
Inactive Indication
Intermittent ClaudicationMyocardial IschemiaPeripheral Arterial Disease
Originator Organization
Valentis, Inc.Valentis, Inc.
Active Organization-
Inactive Organization
ValentisValentisValentis, Inc.Valentis, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Related

1
Clinical Trials associated with Del-1 gene therapy(Valentis, Inc.)
NCT00068133
/ CompletedPhase 2
A Phase II Multicenter, Double-Blind, Placebo-Controlled, Trial of VLTS-589 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease
100 Clinical Results associated with Del-1 gene therapy(Valentis, Inc.)
Login to view more data
100 Translational Medicine associated with Del-1 gene therapy(Valentis, Inc.)
Login to view more data
100 Patents (Medical) associated with Del-1 gene therapy(Valentis, Inc.)
Login to view more data
100 Deals associated with Del-1 gene therapy(Valentis, Inc.)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Intermittent ClaudicationPhase 2
United States
ValentisValentis
01 Jun 2003
Peripheral Arterial DiseasePhase 2
United States
ValentisValentis
01 Jun 2003
Myocardial IschemiaPhase 2-
Valentis, Inc.Valentis, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASGCT2003
ManualManual
Phase 1
Peripheral Arterial Disease
20
ligunehwoy(iokbbrniom) = no serious adverse events attributable to VLTS-589 had been noted in this study lxvjoedcry (rhvibbwhcd )
Positive
01 May 2003
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free